Synthesis and Development of Novel Small-Molecule MEIS2 Inhibitors That Induce Cell Death in Breast Cancer Cells by...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• MEIS proteins are crucial homeobox transcription factors involved in development and increasingly linked to oncogenesis, particularly breast cancer.
• Dysregulation of MEIS proteins can drive cancer progression, highlighting them as potential therapeutic targets.

Purpose of the Study:

• To identify and characterize novel small-molecule inhibitors of MEIS2.
• To evaluate the efficacy and safety of these inhibitors in preclinical models of breast cancer.

Main Methods:

• In silico docking was employed to identify MEIS2 inhibitors targeting the homeobox domain.
• In vitro validation used a MEIS-Luciferase Reporter assay to assess inhibitory potential.
• Breast cancer cell lines were used to determine growth inhibition (IC50) and apoptosis/necrosis induction via flow cytometry.

Main Results:

• Three lead candidates (MEISi-2E, MEISi-3, MEISi-4) were identified with significant binding energies.
• These inhibitors suppressed MEIS-driven activity, downregulated key MEIS genes (Meis1, Meis2), and affected downstream targets.
• Potent inhibition of breast cancer cell growth was observed, with MEISi-3 showing an IC50 of 0.1 μM in SK-BR-3 cells, alongside dose-dependent apoptosis induction.
• Minimal toxicity was noted in healthy human fibroblasts, indicating a favorable safety profile.

Conclusions:

• The identified small molecules are effective MEIS2 inhibitors with potent anti-cancer activity against breast cancer cells.
• These novel inhibitors demonstrate a promising therapeutic potential for targeting MEIS2-dependent pathways in breast cancer treatment.
• The favorable safety profile further supports their development as clinical candidates.